Approved HCV Drugs
Approved HCV Drugs
Boceprevir and Telaprevir Improve Hepatitis C Treatment, Literature Reviews Find
- Details
- Category: HCV Treatment
- Published on Tuesday, 29 January 2013 00:00
- Written by Liz Highleyman
Triple therapy with a direct-acting antiviral drug was more effective than pegylated interferon and ribavirin alone for people with chronic hepatitis C, but there is not yet enough data to determine many differences between boceprevir (Victrelis) and telaprevir (Incivek), or to see effects on long-term clinical outcomes, according to 2 recent medical literature reviews.
AASLD 2012: Telaprevir Twice-daily Works as Well as Every 8 Hours, Safe for Hep C Patients with Cirrhosis
- Details
- Category: HCV Treatment
- Published on Tuesday, 20 November 2012 00:00
- Written by Liz Highleyman
The HCV protease inhibitor telaprevir (Incivek) taken twice-daily with pegylated interferon plus ribavirin is as likely to produce sustained virological suppression as the approved 3-times-daily schedule, with similar safety and tolerability even for people with advanced liver fibrosis, according to study findings presented last week at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) in Boston. 
EASL 2012: Telaprevir 100% Effective for IL28B CC, Adding VX-222 Overcomes Unfavorable Genes
- Details
- Category: HCV Treatment
- Published on Wednesday, 23 May 2012 00:00
- Written by Liz Highleyman
Adding telaprevir (Incivek) to pegylated interferon and ribavirin cured all hepatitis C patients with the favorable IL28B gene pattern, researchers reported at the 47th International Liver Congress (EASL 2012) last month in Barcelona. Another study found that adding the experimental HCV polymerase inhibitor VX-222 raised cure rates even for those with unfavorable IL28B patterns.
Hepatitis C Treatment Reduces HIV Progression and Death in HIV/HCV Coinfected
- Details
- Category: HCV Treatment
- Published on Tuesday, 05 June 2012 00:00
- Written by Liz Highleyman
HIV positive people who achieve sustained virological response (SVR) to interferon-based therapy for chronic hepatitis C not only lower their risk of liver-related complications and death, but also have lower rates of HIV disease progression and all-cause mortality, according to a study published in the May 18, 2012, advance online edition of Clinical Infectious Diseases.
EASL 2012: Ribavirin Dose Reduction Is Effective for Managing Anemia in Patients Using Boceprevir or Telaprevir
- Details
- Category: HCV Treatment
- Published on Tuesday, 08 May 2012 00:00
- Written by Liz Highleyman
Reducing the dose of ribavirin and adding erythropoietin are both good options for managing anemia in hepatitis C patients treated with boceprevir (Victrelis) triple therapy, according to study findings presented at the 47th International Liver Congress (EASL 2012) this week in Barcelona. A related study found that ribavirin reduction also did not impair cure rates with telaprevir (Incivek).
More Articles...
- EASL 2012: GS-7977 with Interferon/Ribavirin Cures Most Treatment-Naive Hepatitis C Patients in 12 Weeks
- AASLD 2011: Sustained Response is Durable among Hepatitis C Patients Treated with Telaprevir
- PegIntron Label Updated to Include Use with New Direct-Acting HCV Agents
- FDA Approves Pegasys Autoinjector for Hepatitis C Patients
Web Design and Development by